EAST SETAUKET, NY, USA I April 25, 2013 I Lixte Biotechnology Holdings, Inc. (LIXT), reported the start of a Phase I trial to determine the appropriate dose of its potentially first-in-class, anticancer compound, LB-100, when given alone and then when given in combination with docetaxel (Taxotere®). Details of the trial underway at an NCI-designated Comprehensive Cancer Center are available in the clinical trials registry: http://clinicaltrials.gov/show/NCT01837667.
Dr. John Kovach, the founder of Lixte said that “LB-100 inhibits an enzyme necessary for cancer cells to recover from damage to DNA. In mouse model systems of human cancers, LB-100 potentiates the activity of widely used anti-cancer regimens that exert their therapeutic benefit by damaging DNA without apparent increases in their toxicity. We hope the same benefit of the combination of LB-100 and known anti-cancer drugs will be seen in patients. In the present trial, LB-100 will be partnered with the versatile drug, docetaxel. As a single agent, docetaxel is the treatment of choice for several common cancers after failure of first-line therapy. Enhancement of the therapeutic benefit of docetaxel for these cancers is the initial goal in the clinical development of our novel DNA-repair disrupter.”
About Lixte Biotechnology Holdings, Inc.
Lixte is a drug discovery company, using biomarker technology to identify enzyme targets associated with serious common diseases and then design novel compounds to attack those targets. Lixte is engaged primarily in development of improved treatments for cancer.
SOURCE: Lixte Biotechnology
Post Views: 121
EAST SETAUKET, NY, USA I April 25, 2013 I Lixte Biotechnology Holdings, Inc. (LIXT), reported the start of a Phase I trial to determine the appropriate dose of its potentially first-in-class, anticancer compound, LB-100, when given alone and then when given in combination with docetaxel (Taxotere®). Details of the trial underway at an NCI-designated Comprehensive Cancer Center are available in the clinical trials registry: http://clinicaltrials.gov/show/NCT01837667.
Dr. John Kovach, the founder of Lixte said that “LB-100 inhibits an enzyme necessary for cancer cells to recover from damage to DNA. In mouse model systems of human cancers, LB-100 potentiates the activity of widely used anti-cancer regimens that exert their therapeutic benefit by damaging DNA without apparent increases in their toxicity. We hope the same benefit of the combination of LB-100 and known anti-cancer drugs will be seen in patients. In the present trial, LB-100 will be partnered with the versatile drug, docetaxel. As a single agent, docetaxel is the treatment of choice for several common cancers after failure of first-line therapy. Enhancement of the therapeutic benefit of docetaxel for these cancers is the initial goal in the clinical development of our novel DNA-repair disrupter.”
About Lixte Biotechnology Holdings, Inc.
Lixte is a drug discovery company, using biomarker technology to identify enzyme targets associated with serious common diseases and then design novel compounds to attack those targets. Lixte is engaged primarily in development of improved treatments for cancer.
SOURCE: Lixte Biotechnology
Post Views: 121
